Molmed in the spotlight. The 5 million euro capital increase for the biotech company with starts this morning headquarters in Milan, within the San Raffaele Biomedical Science Park. It is already known that many shareholders, among which Fininvest stands out, Airain, H-Equity and H-Invest have expressed their willingness to fully subscribe the share reserved for them in option.
In particular, Fininvest, whose subscription quota is equal to 24,903%, has also expressed its interest in subscribing any unopted shares, remaining, however, within the threshold of 30% of the capital.
Molmed also announced last Friday that it had presented to the European Medicines Agency the early entry application for TK, its investigational cell-gene therapy for the treatment of leukemia. After the strong acceleration following the announcement, the Molmed share is still on the Stock Exchange today. By mid-morning, the shares of the biotech company were up 2,32%.
